share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K:外國發行人報告
美股sec公告 ·  05/22 21:24
牛牛AI助理已提取核心訊息
On May 22, 2024, Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced the successful inducement of warrant exercises with accredited holders of the company's Series E and Series F warrants. The agreement resulted in the exercise price of each warrant being reduced to $1.50 per share, and the issuance of replacement warrants, Series G and Series H, which are immediately exercisable and will expire in five and one year(s) respectively. The transaction led to the exercise of 4,358,322 existing warrants, and the company anticipates gross proceeds of approximately $6.5 million before fees and expenses. The proceeds are expected to cover the first year of the eRapa Phase 3 trial obligations and unlock additional non-dilutive funding. The closing of this transaction is expected...Show More
On May 22, 2024, Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced the successful inducement of warrant exercises with accredited holders of the company's Series E and Series F warrants. The agreement resulted in the exercise price of each warrant being reduced to $1.50 per share, and the issuance of replacement warrants, Series G and Series H, which are immediately exercisable and will expire in five and one year(s) respectively. The transaction led to the exercise of 4,358,322 existing warrants, and the company anticipates gross proceeds of approximately $6.5 million before fees and expenses. The proceeds are expected to cover the first year of the eRapa Phase 3 trial obligations and unlock additional non-dilutive funding. The closing of this transaction is expected on the same day, subject to customary conditions. Biodexa Pharmaceuticals also agreed to file a resale registration statement for the shares underlying the Replacement Warrants within fifteen days following the agreement. The company has committed to using the net proceeds for advancing clinical stage assets and for general corporate purposes. Following the exercise of the warrants, Biodexa's issued share capital comprises 4,127,615,322 Ordinary Shares, with each American Depositary Share representing 400 Ordinary Shares.
2024年5月22日,臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC宣佈成功激勵該公司E系列和F系列認股權證的合格持有人行使認股權證。該協議導致每份認股權證的行使價降至每股1.50美元,併發行了G系列和H系列的替代認股權證,這些認股權證可立即行使,並將分別在五年和一年後到期。該交易促成了4,358,322份現有認股權證的行使,該公司預計扣除費用和支出前的總收益約爲650萬美元。預計所得款項將用於支付eRapa第三階段試驗義務的第一年,並解鎖額外的非稀釋資金。該交易預計將於當天完成,但須視慣例條件而定。Biodexa Pharmicals還同意在協議簽署後的十五天內提交替代認股權證基礎股票的轉售註冊聲明。該公司已承諾將淨收益用於推進臨床階段資產和一般公司用途。認股權證行使後,Biodexa的已發行股本包括4,127,615,322股普通股,每股美國存托股代表400股普通股。
2024年5月22日,臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC宣佈成功激勵該公司E系列和F系列認股權證的合格持有人行使認股權證。該協議導致每份認股權證的行使價降至每股1.50美元,併發行了G系列和H系列的替代認股權證,這些認股權證可立即行使,並將分別在五年和一年後到期。該交易促成了4,358,322份現有認股權證的行使,該公司預計扣除費用和支出前的總收益約爲650萬美元。預計所得款項將用於支付eRapa第三階段試驗義務的第一年,並解鎖額外的非稀釋資金。該交易預計將於當天完成,但須視慣例條件而定。Biodexa Pharmicals還同意在協議簽署後的十五天內提交替代認股權證基礎股票的轉售註冊聲明。該公司已承諾將淨收益用於推進臨床階段資產和一般公司用途。認股權證行使後,Biodexa的已發行股本包括4,127,615,322股普通股,每股美國存托股代表400股普通股。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。